Minisymposium: Covalent inhibitors in Drug Discovery


Some of the worlds most widely used drugs, e.g. acetylsalicylic acid, penicillins, omeprazole, clopidogrel, etc, are all based on covalent inhibition of the target enzyme. However, few drugs are designed to be covalent, and the pharmaceutical industry is still cautious for this mode-of-action due to an inherent risk of late stage idiosyncratic toxicology. In this workshop we gather industrial and academic experts to review state-of-the-art and shed some light on this perplexity. Please, take the chance to discuss your own project with the speakers during the day.

Most welcome!
The organizing committee
Ylva Gravenfors, Ulrika Yngve & Per Arvidsson
SciLifeLab Drug Discovery and Development Platform

Programme

09:00
Registration and Coffee
09.30
Introduction
09.40
Covalent Kinase Inhibitor Drugs: The Future is Already Here

Tjeerd Barf, Acerta Pharma, Netherlands

10.30
Safety first: Covalent inhibitors from a safety perspective

Mickael Mogemark, Astra Zeneca, Sweden

11:20
Reversible covalent inhibitors of cathepsins

Lourdes Salvador Oden, Medivir, Sweden

11.50
Lunch
12.40
Utilizing a covalent mechanism for target identification and development of a STAT3 inhibitor prodrug

Martin Johansson, Glactone Pharma Development, Sweden

13:10
Bioanalysis of a soft and highly reactive electrophile

Lars Hagberg, Aprea, Sweden

13:40
Conclusions


Evaluation

Thank you for helping us improve by filling out this brief evaluation form.

Please select a valid form